A tale of two plaques: convergent mechanisms of T-cell-mediated inflammation in psoriasis and atherosclerosis

:  Psoriasis and atherosclerosis are diseases in which effector T lymphocytes such as Helper T cells type 1 (Th1) and 17 (Th17) play integral roles in disease pathogenesis and progression. Regulatory T cells (Treg) also exert clinically important anti‐inflammatory effects that are pathologically alt...

Full description

Saved in:
Bibliographic Details
Published in:Experimental dermatology 2011-07, Vol.20 (7), p.544-549
Main Authors: Armstrong, April W., Voyles, Stephanie V., Armstrong, Ehrin J., Fuller, Erin N., Rutledge, John C.
Format: Article
Language:English
Subjects:
Animals
Arteriosclerosis
atherosclerosis
Atherosclerosis (general aspects, experimental research)
Atherosclerosis - drug therapy
Atherosclerosis - immunology
Biological and medical sciences
Blood and lymphatic vessels
Cardiology. Vascular system
CD4-Positive T-Lymphocytes - immunology
Dermatology
Drug development
Heart diseases
Helper cells
Humans
Immunoregulation
Inflammation
Inflammation - drug therapy
Inflammation - immunology
Lymphocytes T
Medical sciences
Plaques
Psoriasis
Psoriasis - drug therapy
Psoriasis - immunology
Psoriasis. Parapsoriasis. Lichen
regulatory T cells
T-helper 1 cells
T-helper 17 cells
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary::  Psoriasis and atherosclerosis are diseases in which effector T lymphocytes such as Helper T cells type 1 (Th1) and 17 (Th17) play integral roles in disease pathogenesis and progression. Regulatory T cells (Treg) also exert clinically important anti‐inflammatory effects that are pathologically altered in psoriasis and atherosclerosis. We review the immunological pathways involving Th1, Th17 and Treg cells that are common to psoriasis and atherosclerosis. These shared pathways provide the basis for mechanisms that may explain the epidemiologic observation that patients with psoriasis have an increased risk of heart disease. Improved understanding of these pathways will guide future experiments and may lead to the development of therapeutics that prevent or treat cardiovascular complications in patients with psoriasis.
ISSN:0906-6705
1600-0625
DOI:10.1111/j.1600-0625.2011.01308.x